Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
APOL1-associated nephropathy typically occurs in association with certain environmental factors or systemic diseases.
|
31601430 |
2020 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
APOL1 nephropathy risk alleles.
|
31563468 |
2020 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Transplant physicians should inform potential living kidney donors at-risk for APOL1-associated nephropathy about the gene and possibility of genetic testing early in the donor evaluation, well before scheduling the donor nephrectomy.
|
31449181 |
2020 |
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Urinary JCPyV was associated with paradoxically lower rates of nephropathy in those with APOL1 high-risk genotypes.
|
30320619 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Heterogeneity in study population and study design has led to differing reports on the role of APOL1 nephropathy risk variants in CVD.
|
31082862 |
2019 |
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These data, coupled with anecdotal case reports and a recent cohort study of living donors, raise important questions about the potential increased kidney disease risk for living donors with APOL1 risk variants and the need for testing as part of the standard living donor evaluation process.
|
30982552 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Further studies to identify additional second hits are necessary to better understand the pathologic mechanisms of donor APOL1-associated kidney disease in the recipient.
|
30054024 |
2019 |
Kidney Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
APOL1 is expressed in renal cells, however, the pathogenic events that lead to renal cell damage and kidney disease are not fully understood.
|
31661509 |
2019 |
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We determined the frequency and association of <i>(APOL1)</i> risk alleles with markers of kidney disease in black South Africans with hypertension-attributed chronic kidney disease (CKD) and their first-degree relatives.
|
30369398 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The APOL1-associated spectrum of nondiabetic nephropathy also includes proteinuric kidney diseases, idiopathic focal segmental glomerulosclerosis, collapsing glomerulopathy, severe lupus nephritis, and sickle cell nephropathy.
|
31023447 |
2019 |
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This study will examine the increasing prevalence of kidney diseases in HIV-positive adults in a West African population, and the relationship between these diseases and the APOL1 high-risk genotype.
|
31182139 |
2019 |
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
By contrast, the significant survival advantage of AA dialysis patients was not observed in patients with ESRD attributed to other kidney disease (including polycystic kidney disease, interstitial nephritis, and pyelonephritis) and other GN, which are not associated with APOL1 variants.
|
30995638 |
2019 |
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
However, only a minority of people with APOL1-associated risk develops kidney disease and specific clinical measures to address APOL1-associated risk are lacking.
|
31480040 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, IONIS-APOL1Rx may be an effective therapeutic for APOL1 nephropathies and warrants further development.
|
31217349 |
2019 |
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Variants of the APOL1 gene found in AAs are associated with a higher rate of kidney disease and play a complex role in cardiovascular disease.
|
31532792 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Although APOL1-associated kidney disease is thought to account for a substantial proportion of ESKD in African Americans, not all the increased risk for ESKD is accounted for, and a complete cataloging of disparities in genetic causes of ESKD eludes our current understanding of genetic-associated kidney disease.
|
31606237 |
2019 |
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Two APOL1 alleles (G1 and G2) have been identified as risk factors for sickle cell disease nephropathy.
|
31158233 |
2019 |
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Approximately 12-13% of African Americans have two renal risk APOL1 variants but most do not develop kidney disease.
|
30507707 |
2019 |
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Studies addressing the function of APOL1 and how the CKD-associated APOL1 variants cause kidney disease are challenging and remain to be fully investigated under conditions that faithfully model known human genetics and physiology.
|
30332315 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition to APOL1 testing, the role of diagnostic exome sequencing in evaluating potential transplant recipients and donors with a positive family history of kidney disease is discussed.
|
31590185 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
We explore APOL1 nephropathy and Balkan nephropathy as examples of CKD clustering that illustrate genetics and environment conspiring to cause high rates of kidney disease.
|
30451737 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Along with major progress that had been achieved in the field of APOL1 nephropathy, controversies and enigmatic issues persist.
|
30431460 |
2019 |
Kidney Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The evolving understanding of the pathogenesis in APOL1-associated nephropathy will identify biomarkers predicting nephropathy in individuals at high genetic risk and lead to novel therapies to prevent or slow native CKD progression and prolong survival of transplanted kidneys.
|
30371607 |
2019 |
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The discovery of apolipoprotein L1 (APOL1) gene variants and its association with kidney disease in African-Americans represent a significant breakthrough in understanding the genetic basis of ancestry-based differences in a public health problem.
|
31050035 |
2019 |
Kidney Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The ability of G0 APOL1 to recruit risk variant APOL1 to LDs may help explain the recessive pattern of kidney disease inheritance.
|
30733285 |
2019 |